Investigating tumor promotion in the postpartum liver metastatic niche



ARCS ADVANCING SCIENCE IN AMERICA

- Postpartum breast cancer (PPBC) is defined as breast cancer diagnosed within 10 years of a pregnancy. PPBC patients are more likely than their never-pregnant (nulliparous) counterparts to develop liver metastases (Figure 1)
- Metastasis seems to be driven by host biology, as poor prognosis is independent of biologic subtype, tumor size, age at diagnosis, and year of diagnosis



OREGON HEALTH&SCIENCE

Figure 1. a) Frequency of liver metastasis in nulliparous and PPBC patients from a University of Colorado (UCH) cohort, N=563; p=0.03; Logistic regression multivariate analysis. b) Frequency of liver (p=0.04, OR: 4.12), lung (p=1.00, OR: 1.10), and bone metastasis (p=0.11, OR: 0.50) in a combined young women's breast cancer cohort from UCH and Dana-Farber Cancer Institute (DFCI) demonstrates tissue-tropism for metastases to the liver, N=117; Fisher's exact. Goddard et al, 2017.

The liver in postpartum young women preferentially supports liver metastasis.

Unique postpartum liver biology that may facilitate metastasis: weaning-induced liver involution



across the reproductive cycle



d) Cell death drives liver weight loss post-weaning



c) Proliferation drives liver size increase in pregnancy and lactation



e) Liver metabolism supports liver expansion and involution



Figure 2. a) Breeding schema. b) Sprague-Dawley (SD) rat liver weights from nulliparous (N), pregnancy (P), lactation (L), days 2, 4, 6, 8, 10 post-weaning (involution, Inv2, Inv4, etc), and regressed stages (R). c Ki67 positive rat hepatocytes d) Cleaved caspase-3 western blot from pooled liver lysates. e) Metabolite zscores showing an energy metabolism signature detected by mass-spectrometry at lactation and a cell stress signature at involution day 8 in rat livers (average of n=4-6 rats/grp). * p: <0.05, ** p:<0.01, *** p: <0.001, One-way ANOVA (Goddard et al, February 2017)

and e) single tumor cells found in livers of nulliparous or involution day 2 mice injected with D2OR-GFP tumor cells and sacrificed 3 days post-tumor cell injection; Student's t test, * p: <0.05, ** p:<0.01

Future (ongoing) direction: Assess if involution metastatic promotion emerges by day 14 post tumor cell injection

Hypothesis: Metastatic advantage in involution may be immunemediated; single tumor cells may preferentially avoid immune clearance.

Premise: The involution liver environment is enriched for immune suppressive features that may promote metastasis.

Figure 8. a) Principal component analysis illustrates distinct lipid profiles across reproductive and involution day 2 mice (n=5/group); all p-values: unpaired Student's T-test

Acknowledgements: Authors appreciate the support of Schedin lab members, in particular Alex Klug for animal support and Sonali Jinal, Jay Narasimhan, and Andrea Calhoun for histological support. Authors would like to thank Lalage M. Wakefield, NCI for gift of original "glowing head" breeding pair and the UC Denver Lipidomics core for mass spectrometry analysis. Works Cited:

Callihan, E.B., et al., Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat, 2013. **138**(2): p. 549-59. 2. Goddard et al, The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis. Cancer

Discovery 2017; 7(2): 1-11.

3. Goddard et al, A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer. J. Vis. Exp. 2016; 118. 4. Herber, DL., et al. Lipid accumulation and dendritic cell dysfunction in cancer. *Nat Med.* 2010 16(8): 880-886. doi: 10.1038/nm.2172

5. Beloribi-Djefaflia, S. et al. Lipid metabolic reprogramming in cancer cells. Oncogenesis (2016) 5, e189; doi:10.1038/oncis.2015.49.

Funding: OHSU Cancer Biology Program Student Stipend; Ruth L Kirschstein T32 PERT Training Grant; ARCS Foundation Oregon Scholarship; NIH 5 R01 CA169175H to P.S.

